Skip to content
Peptide.Guide
PreclinicalLongevitySubQResearch protocolsPartial data

Tat-Beclin-1

Autophagy-inducing peptide that enhances Beclin-1 activity, studied for neurodegeneration and infection in preclinical models.

§ 01   Overview

Overview

Autophagy-inducing peptide that enhances Beclin-1 activity, studied for neurodegeneration and infection in preclinical models.

Published preclinical work; no human trials.

§ 02   Mechanism

Mechanism of action

Tat-Beclin-1 is a cell-penetrating peptide fused to a region of Beclin-1. It competes with GAPR-1 to free Beclin-1, enhancing autophagy initiation.

  • 01Autophagy induction in preclinical models
  • 02Potential neuroprotective effects

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
Not characterized
Route
SubQ
Frequency
Research protocols

§ 04   Evidence

Evidence & research

Preclinical

Published preclinical work; no human trials.

FDA Status

Not FDA-approved.

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Unknown in humans

Contraindications

None specified.

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.